Our representatives located in the West, Midwest, Northeast and South regions of the United States are dedicated to providing customers with on-site support and solutions unique to their processes based on our expertise in virus removal filtration and bioprocessing.
The regional head office for North and South America in Glenview, Illinois has developed a state-of-the-art research and development facility to support and collaborate with users of Planova™ filters in the Americas and throughout the world.
The phage laboratory is a Biosafety Level 2+ facility held under negative pressure and features a biological safety cabinet for maximum safety when working with the BSL2 host agent, Pseudomonas aeruginosa.
Bacteriophages provide unique systems for evaluating virus removal in filtration processes. Structurally similar to mammalian viruses, bacteriophage stocks can be produced with significantly higher titers and require shorter assay time.
PP7 phage is small, non-enveloped, and infects the bacterial host P. aeruginosa. Based on its size and shape, PP7 phage is an excellent model for small, non-enveloped viruses such as parvoviruses.
Porcine parvovirus(PPV) *
PP7 phage *
|Diameter (nm)||18 - 26||23 – 28|
|Stock titer (log PFU/mL)||8 - 9||10 - 11|
|Infectivity assay time (days)||≥10||1|
*From the VIPERdb website, http://viperdb.scripps.edu/
The following clearance study data using 5 g BSA/L feed spiked with 0.1% PP7 on Planova™ 15N, 20N, and BioEX filters demonstrate the suitability of our PP7 phage stock as a model for PPV.
|Filter||Load titer |
|Permeate titer |
The Glenview, IL regional head office is also home to Asahi Kasei Bioprocess equipment manufacturing operations. Bringing these resources together provides opportunities to expand Planova™ filter studies to include large-scale control and automation strategies.